Abstracts tagged "glucocorticoids"

Abstract Number: 0458 • ACR Convergence 2022
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
Despina Michailidou¹, Tianyu Zhang², Andreas Diamantopoulos³, Pavlos Stamatis⁴ and Bernard Ng⁵, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Akershus University Hospital, Lørenskog, Norway, ⁴Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ⁵Rheumatology Section, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is an independent risk factor for thromboembolic events. The purpose of our study was to identify prognostic factors for thromboembolic…
Abstract Number: 1041 • ACR Convergence 2022
Tofacitinib in Refractory Uveitis – an Observational Study
Nikhil Gupta¹ and Deepankur Mahajan², ¹Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, ²Mahajan Eye Centre, New Delhi, India
Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 0459 • ACR Convergence 2022
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
Hampus Henningson¹, Björn Hammar², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Ophthalmology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the age-group 50 years and older. Cranial involvement is common and can lead to…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 0460 • ACR Convergence 2022
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Naomi Patel¹, Xiaoqing Fu², yuqing zhang³ and John Stone⁴, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Naomi Patel¹, David Jayne², Peter Merkel³, Pirow Bekker⁴, yuqing zhang⁵, Huibin Yue⁴ and John Stone⁶, ¹Massachusetts General Hospital, Sale Creek, TN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴ChemoCentryx, San Juan Capistrano, CA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
Abstract Number: 2072 • ACR Convergence 2022
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Ilana Usiskin and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…
Abstract Number: 1398 • ACR Convergence 2021
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
Alojzija Hocevar¹, Rok Jese¹, Jelka Kramaric², Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²UKC Ljubjana, Ljubjana, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Jesús T. Sánchez-Costa¹, Iñigo Hernández-Rodríguez², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Jesús A. Valero-Jaimes⁵, Ismael González-Fernández⁶, Julio Sánchez⁷, Judit Lluch⁸, Eva Galindez-Agirregoikoa⁹, Javier Mendizábal-Mateos¹⁰, Pia M. Lois Bermejo¹¹, Javier Loricera¹², Alejandro Muñoz¹³, Cristina Valero-Martínez¹⁴, Patricia Moya¹⁵, Carmen Larena-Grijalba¹⁶, Vanessa A. Navarro-Angeles¹⁷, Joan Calvet-Fontova¹⁸, Ivette Casafont¹⁹, Francisco Ortiz-Sanjuán²⁰, Selene Labrada-Arrabal²¹, Jaime Calvo-Alén²², Carlota L. Iñiguez-Ubiaga²³, Vanesa Hernández²⁴, Cristina Campos-Fernández²⁵, María Alcalde-Villar²⁶, Antonio Juan-Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal³¹, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³², ¹Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰H. Navarra, Navarra, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁴Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁰H. La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…
Abstract Number: 1416 • ACR Convergence 2021
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
Idil Esen¹, Philip Therkildsen², Berit Dalsgaard Nielsen², Anna van 't Ende¹, Annemieke Boots¹, Peter Heeringa¹, Ellen-Margrethe Hauge², Elisabeth Brouwer¹ and Yannick van Sleen³, ¹University Medical Center Groningen, Groningen, Netherlands, ²Aarhus University Hospital, Aarhus, Denmark, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
Abstract Number: 1428 • ACR Convergence 2021
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Shirley Cohen-Mekelberg², Bryant England³, Ted Mikuls³, Daniel Clauw⁴, Wyndy Wiitala², Rodney Hayward⁵, Jeremy Sussman⁶ and Akbar Waljee⁵, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ⁶University of Michigan; VA Ann Arbor Healthcare System; Center for Clinical Management Research, Ann Arbor, MI
Background/Purpose: A third of RA patients use long-term glucocorticoids (GCs) despite a known dose-dependent association with major adverse cardiovascular (CV) events (MACE). Prior work suggests…
Abstract Number: 0120 • ACR Convergence 2021
Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
Beth Wallace¹, Meriah Moore², Andrew Heisler³, Lutfiyya Muhammad⁴, Jing Song⁵, Daniel Clauw², Clifton Bingham⁶, Marcy Bolster⁷, Wendy Marder², Tuhina Neogi⁸, Alyssa Wohlfahrt⁹, Dorothy Dunlop¹⁰ and Yvonne Lee¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Bronson Rheumatology Specialists, Kalamazoo, MI, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Worthington, IL, ⁶Johns Hopkins University, Baltimore, MD, ⁷Massachusetts General Hospital, Boston, MA, ⁸Boston University School of Medicine, Boston, MA, ⁹Tufts University School of Medicine, Boston, MA, ¹⁰Northwestern University, Chicago, IL
Background/Purpose: Over one-third of patients with rheumatoid arthritis (RA) exhibit evidence of fibromyalgianess, a cluster of somatic symptoms associated with increased sensitivity to painful stimuli.…
Abstract Number: 1642 • ACR Convergence 2021
Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Roberta Berard¹, Michael Rieder², Erkan Demirkaya², Michael Miller³ and Renee Pang², ¹London Health Sciences Centre, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³University of Western Ontario, Children's Research Institute, London, ON, Canada
Background/Purpose: Prednisone is a glucocorticoid (GC) medication commonly used in moderate ( >7.5 mg per day) to high doses (≥ 1 mg/kg/day) for children with…

« Previous Page
1
…
8
9
10
11
12
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].